ICD-inducing drugs enhance tumor antigen exposure and promote the release of immunostimulatory tumor cell content-related proteins, such as calreticulin (CRT), adenosine triphosphate (ATP), and high mobility group box 1 (HMGB1) (7, 8). This evidence concerns the gene CALR and neoplasm.